Cancer Advisor

Introduction Interest in repurposing antiparasitic drugs for oncology has expanded rapidly over the past decade. Compounds such as ivermectin, mebendazole, and fenbendazole have moved from parasitology into experimental cancer biology discussions due to observed anticancer activity in preclinical models. A recent article published by Pharmacy Times titled “ From Farm to Pharmacy: Controversial Antiparasitics in Cancer Care ” provides a cautious, evidence-based critique of this trend, emphasizing the lack of clinical validation and potential safety concerns. However, newer scientific literature—including mechanistic reviews and early-phase clinical trials—suggests a more nuanced picture: biological activity is real, but clinical efficacy remains unproven. 1. Mechanistic Evidence: Why These Drugs Enter Oncology Research A comprehensive ScienceDirect review highlights that ivermectin is not limited to antiparasitic action. It exhibits multi-pathway anticancer activity , including: inhibi...

From “Undruggable” to One of the Most Important Targets in Cancer Medicine For decades, KRAS mutations were considered one of the most challenging problems in oncology. The protein was structurally smooth, biologically complex, and notoriously resistant to drug binding. It became known in medical literature as “undruggable.” That narrative changed dramatically in the early 2020s. Today, KRAS is no longer a scientific dead end—it is one of the most actively targeted oncogenic drivers in modern precision medicine. Multiple generations of KRAS inhibitors now exist, and treatment strategies are evolving from single-mutation targeting toward pan-RAS pathway control and combination therapy systems . However, despite major breakthroughs, KRAS-driven cancers remain difficult to cure. The reason is not a lack of drugs—but the adaptability of cancer biology itself. This article provides a complete 2026 update on KRAS inhibitors, including mechanisms, approved therapies, emerging drugs, resistanc...

Medically Reviewed by: OneDayMD Editorial Team Last Updated: May 2026 Abstract Metabolic therapy for cancer, including ketogenic diets (KD), fasting-mimicking diets (FMD), caloric restriction, hyperbaric oxygen therapy (HBOT), and metabolically supported chemotherapy (MSCT), has gained increasing scientific and public interest. However, clinical outcomes remain heterogeneous, with some tumours appearing metabolically vulnerable while others demonstrate adaptive resistance or even paradoxical growth under ketogenic conditions. Emerging evidence suggests that tumour genomic and metabolic phenotypes may determine therapeutic responsiveness. This review proposes a genomics-guided metabolic oncology framework centered on ketolytic competency markers such as OXCT1 and BDH1, integrating tumour genomics, metabolic flexibility, and real-world clinical case patterns across breast cancer, glioblastoma (GBM), lung cancer, and prostate cancer. The framework synthesizes evidence from genomic studies...

2025 Se-Hoon Kim et al - Abemaciclib induces G1 arrest and lysosomal dysfunction in canine melanoma cells: synergistic effects with Fenbendazole. (1) Highlights  Abemaciclib (VERZENIO), a CDK4/6 inhibitor, is well-established for treating hormone receptor-positive and HER2-negative (HR+/HER2−) human breast cancer. Five canine melanoma (skin cancer) cell lines were used to evaluate the antitumor effects of abemaciclib.  Synergistic effects with fenbendazole were evaluated. RESULTS: Abemaciclib induced G1 cell cycle arrest, autophagy (but not apoptosis) Co-treatment with fenbendazole enhanced cytotoxicity and showed synergistic effects within specific dose ranges. Mouse tumors were smaller. mouse body weight remained same (treatment was well tolerated). Synergistic interaction with Fenbendazole suggests a potential combinatorial therapeutic approach for canine melanoma. CONCLUSION: This study showed that a new generation Targeted therapy for breast cancer (abemaciclib) or VER...

Abstract Background Repurposed antiparasitic agents including Ivermectin, Fenbendazole, and Mebendazole have gained substantial public attention as potential adjunctive therapies for colorectal cancer. Online compilations of anecdotal reports have expanded rapidly following social media amplification, celebrity endorsements, and physician-curated testimonial series. ( onedaymd.com ) Objective To systematically reorganize and critically analyze 79 published colorectal cancer case reports and testimonials involving ivermectin-, fenbendazole-, or mebendazole-based regimens, with emphasis on tumour biology, metastatic patterns, regimen heterogeneity, evidence hierarchy, and potential sources of bias. Methods A structured qualitative evidence-mapping analysis was conducted using publicly available case reports and testimonials compiled in a widely circulated colorectal cancer review article published by OneDayMD. Cases were stratified by cancer subtype, disease stage, metastatic distrib...

Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...